rolipram has been researched along with Idiopathic Parkinson Disease in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cognitive impairment often occurs in Parkinson's disease (PD), but the mechanism of onset remains unknown." | 1.46 | Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. ( Ishii, T; Kinoshita, KI; Muroi, Y; Unno, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, L | 1 |
| Huang, C | 1 |
| Zhong, J | 1 |
| He, J | 1 |
| Guo, J | 1 |
| Liu, M | 1 |
| Xu, JP | 1 |
| Wang, HT | 1 |
| Zhou, ZZ | 1 |
| Kinoshita, KI | 1 |
| Muroi, Y | 1 |
| Unno, T | 1 |
| Ishii, T | 1 |
| Niccolini, F | 1 |
| Wilson, H | 1 |
| Pagano, G | 1 |
| Coello, C | 1 |
| Mehta, MA | 1 |
| Searle, GE | 1 |
| Gunn, RN | 1 |
| Rabiner, EA | 1 |
| Foltynie, T | 1 |
| Politis, M | 1 |
| Casacchia, M | 1 |
| Meco, G | 1 |
| Castellana, F | 1 |
| Bedini, L | 1 |
| Cusimano, G | 1 |
| Agnoli, A | 1 |
| Parkes, JD | 1 |
| Thompson, C | 1 |
| Brennan, L | 1 |
| Gajraj, N | 1 |
| Howcroft, B | 1 |
| Ruiz, J | 1 |
1 trial available for rolipram and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Humans; Lisuride; Middle Aged; Parkinson Disease; Pyrroli | 1983 |
4 other studies available for rolipram and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
Topics: Animals; Benzylamines; Cell Survival; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Re | 2019 |
Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cyclic AMP; Cyclic AMP Resp | 2017 |
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain Mapping; Carbon Radioisotopes; Cognition | 2017 |
Rolipram in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Ergot Alkaloids; Humans; Levodopa; Parkinson Diseas | 1984 |